Evaluation of Curcumin Formulation, and Ashwagandha Root Powder Extract in the Management of Advanced High Grade Osteosarcoma"
Eligibility criteria
1. Osteosarcoma which has relapsed after treatment and for which no second line
chemotherapy is planned and in which disease is not amenable to surgery.
2. Patient should be able to follow-up 3 monthly for clinical and imaging assessment as
well as biochemical tests
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
response, toxicity, disease progression
2 years
Yes
India: Drugs Controller General of India
381
NCT00689195
May 2008
June 2013
Name | Location |
---|